AU2013272014B2 - NMR measurements of GlycA - Google Patents

NMR measurements of GlycA Download PDF

Info

Publication number
AU2013272014B2
AU2013272014B2 AU2013272014A AU2013272014A AU2013272014B2 AU 2013272014 B2 AU2013272014 B2 AU 2013272014B2 AU 2013272014 A AU2013272014 A AU 2013272014A AU 2013272014 A AU2013272014 A AU 2013272014A AU 2013272014 B2 AU2013272014 B2 AU 2013272014B2
Authority
AU
Australia
Prior art keywords
glyca
nmr
hdl
risk
density lipoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013272014A
Other languages
English (en)
Other versions
AU2013272014A1 (en
Inventor
Dennis W. Bennett
James D. Otvos
Irina Y. Shalaurova
Justyna E. WOLAK-DINSMORE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liposcience Inc
Original Assignee
Liposcience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposcience Inc filed Critical Liposcience Inc
Publication of AU2013272014A1 publication Critical patent/AU2013272014A1/en
Application granted granted Critical
Publication of AU2013272014B2 publication Critical patent/AU2013272014B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0044—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/4625—Processing of acquired signals, e.g. elimination of phase errors, baseline fitting, chemometric analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2576/00—Medical imaging apparatus involving image processing or analysis
    • A61B2576/02—Medical imaging apparatus involving image processing or analysis specially adapted for a particular organ or body part
    • A61B2576/023—Medical imaging apparatus involving image processing or analysis specially adapted for a particular organ or body part for the heart
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Signal Processing (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Ecology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Artificial Intelligence (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Cardiology (AREA)
AU2013272014A 2012-06-08 2013-05-30 NMR measurements of GlycA Active AU2013272014B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261657315P 2012-06-08 2012-06-08
US61/657,315 2012-06-08
US201261711471P 2012-10-09 2012-10-09
US61/711,471 2012-10-09
US201261739305P 2012-12-19 2012-12-19
US61/739,305 2012-12-19
US13/830,199 2013-03-14
US13/830,199 US9470771B2 (en) 2012-06-08 2013-03-14 NMR measurements of NMR biomarker GlycA
PCT/US2013/043343 WO2013184483A1 (en) 2012-06-08 2013-05-30 Nmr measurements of glyca

Publications (2)

Publication Number Publication Date
AU2013272014A1 AU2013272014A1 (en) 2014-12-18
AU2013272014B2 true AU2013272014B2 (en) 2017-05-25

Family

ID=49712504

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013272014A Active AU2013272014B2 (en) 2012-06-08 2013-05-30 NMR measurements of GlycA

Country Status (9)

Country Link
US (3) US9470771B2 (enExample)
EP (3) EP4439587A3 (enExample)
JP (1) JP6177899B2 (enExample)
CN (1) CN104508471B (enExample)
AU (1) AU2013272014B2 (enExample)
CA (2) CA3146947A1 (enExample)
FI (1) FI3839544T3 (enExample)
SG (1) SG11201407803TA (enExample)
WO (1) WO2013184483A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9076342B2 (en) 2008-02-19 2015-07-07 Architecture Technology Corporation Automated execution and evaluation of network-based training exercises
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US20140358451A1 (en) * 2013-06-04 2014-12-04 Arizona Board Of Regents On Behalf Of Arizona State University Fractional Abundance Estimation from Electrospray Ionization Time-of-Flight Mass Spectrum
WO2015079000A1 (en) * 2013-11-27 2015-06-04 Institut D'investigació Sanitària Pere Virgili Method for the characterization of lipoproteins
JP6696907B2 (ja) * 2014-01-06 2020-05-20 リポサイエンス，インコーポレイテッド 糖尿病への転化を予測する多重マーカリスクパラメータ
CN107110939B (zh) * 2014-09-11 2021-05-14 力保科学公司 用于测定心血管疾病或事件的风险参数的系统
WO2016065633A1 (zh) 2014-10-31 2016-05-06 华为技术有限公司 一种曲线拟合电路、模拟预失真器和射频信号发射机
US10803766B1 (en) 2015-07-28 2020-10-13 Architecture Technology Corporation Modular training of network-based training exercises
US10083624B2 (en) 2015-07-28 2018-09-25 Architecture Technology Corporation Real-time monitoring of network-based training exercises
EP3258285B1 (en) 2016-06-14 2020-10-21 Bruker BioSpin GmbH Method for predicting chemical shift values of nmr spin systems in a sample of a fluid class, in particular in a sample of a biofluid
DE102016224691A1 (de) * 2016-12-12 2018-06-14 Numares Ag Verfahren zur Analyse eines NMR-Spektrums einer lipoproteinhaltigen Probe
FI20177098A1 (fi) * 2017-08-29 2019-03-01 Leppaeluoto Juhani Menetelmiä ja laitejärjestelyitä diabeteksen, sydän- ja verisuonisairauksien, tulehdusten, dementian ja kuolleisuuden riskejä vähän liikkuvilla henkilöillä vähentävän liikunnan kynnysarvojen määrittämiseen
CA3073827C (en) 2017-09-07 2023-10-17 Liposcience, Inc. Multi-parameter metabolic vulnerability index evaluations
CN107796946B (zh) * 2017-10-20 2019-10-25 中国医学科学院基础医学研究所 尿液中冠心病的蛋白标志物及其用途
WO2019094879A1 (en) * 2017-11-10 2019-05-16 Liposcience, Inc. Methods and systems to detect and quantify the amount of lp-x and other abnormal lipoproteins in a biosample using nmr spectroscopy
WO2019143801A1 (en) * 2018-01-18 2019-07-25 New York University System and method for blood glucose monitoring using magnetic resonance spectroscopy
CN109805898B (zh) * 2019-03-22 2024-04-05 中国科学院重庆绿色智能技术研究院 基于注意力机制时序卷积网络算法的危重症死亡预测方法
US11887505B1 (en) 2019-04-24 2024-01-30 Architecture Technology Corporation System for deploying and monitoring network-based training exercises
EP4281768A1 (en) * 2021-01-22 2023-11-29 Bruker BioSpin MRI GmbH Infection diagnosis and characterization using diffusion and relaxation edited proton nmr spectroscopy
CN116848409A (zh) * 2021-01-22 2023-10-03 布鲁克碧奥斯平有限公司 使用扩散和弛豫编辑的质子nmr谱的感染诊断和表征
FI130189B (fi) * 2021-02-19 2023-04-03 Nightingale Health Oyj Menetelmä sappirakon häiriön kehittymisriskin määrittämiseksi kohteelle
CN120035761A (zh) 2022-08-05 2025-05-23 美国控股实验室公司 通过nmr分析代谢易损性
DE102023110285B3 (de) 2023-04-21 2024-05-08 Universität zu Lübeck, Körperschaft des öffentlichen Rechts Nmr-messung von glykoproteinen

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529710A (en) 1981-06-12 1985-07-16 The United States Of America As Represented By The United States Department Of Energy Method of using a nuclear magnetic resonance spectroscopy standard
JPH0698036B2 (ja) 1986-10-20 1994-12-07 小野薬品工業株式会社 アミノ酸の選択的定量法
US4933844A (en) 1988-09-26 1990-06-12 Otvos James D Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer
US6653140B2 (en) * 1999-02-26 2003-11-25 Liposcience, Inc. Methods for providing personalized lipoprotein-based risk assessments
AU2054000A (en) 1999-02-26 2000-09-14 Lipomed, Inc. Methods, systems, and computer program products for analyzing and presenting risk assessment results based on nmr lipoprotein analysis of blood
EP1171778B1 (en) 1999-04-22 2006-03-01 Liposcience, Inc. Nmr-method for determining the risk of developing type 2 diabetes
CA2331116A1 (en) 2001-01-15 2002-07-15 Chenomx, Inc. Compound identification and quantitation in liquid mixtures -- method and process using an automated nuclear magnetic resonance measurement system
US6617167B2 (en) 2001-08-01 2003-09-09 Liposcience, Inc. Method of determining presence and concentration of lipoprotein X in blood plasma and serum
EP1540560B1 (en) 2002-06-14 2011-03-16 Pfizer Limited Metabolic phenotyping
AU2003285926A1 (en) 2002-10-25 2004-05-25 Liposcience, Inc. Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals
WO2004085996A2 (en) 2003-03-20 2004-10-07 Albert Einstein College Of Medicine Of Yeshiva University Biomarkers for longevity and disease and uses thereof
WO2005043171A1 (en) 2003-10-23 2005-05-12 Liposcience, Inc. Methods, systems and computer programs for assessing chd risk using mathematical models that consider in vivo concentration gradients of ldl particle subclasses of discrete size
AU2005230449B2 (en) 2004-04-01 2010-02-18 Liposcience, Inc. NMR clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples
WO2006057081A1 (en) 2004-11-24 2006-06-01 Mitsuyo Okazaki Method for analyzing lipoproteins
JP5006524B2 (ja) 2005-05-13 2012-08-22 株式会社日立製作所 緩和時間特定のためのｎｍｒ装置の信号処理方法
JP4358814B2 (ja) 2005-11-09 2009-11-04 花王株式会社 試料の解析方法
ES2525345T3 (es) 2006-03-24 2014-12-22 Metanomics Gmbh Procedimiento de diagnóstico de diabetes de tipo II
WO2007133593A2 (en) 2006-05-10 2007-11-22 Liposcience, Inc. Methods, systems and computer programs for assessing chd risk using weighted hdl particle number measurements
WO2008137075A2 (en) 2007-05-02 2008-11-13 President And Fellows Of Harvard College Compositions and methods for the treatment of metabolic disorders and inflammation
US7923257B2 (en) 2007-05-04 2011-04-12 Perkinelmer Health Sciences, Inc. Detecting isomers using differential derivatization mass spectrometry
EP2019311A1 (en) 2007-07-23 2009-01-28 F.Hoffmann-La Roche Ag A method for detecting a target substance by nuclear magnetic resonance
US20110311650A1 (en) 2008-07-07 2011-12-22 Thomas Wang Multiplexed biomarkers of insulin resistance
WO2010047767A2 (en) 2008-10-20 2010-04-29 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same
US20120122981A1 (en) 2009-03-31 2012-05-17 Yun Fu Hu Biomarkers Related to Insulin Resistance and Methods using the Same
US8741788B2 (en) 2009-08-06 2014-06-03 Applied Materials, Inc. Formation of silicon oxide using non-carbon flowable CVD processes
US7935643B2 (en) 2009-08-06 2011-05-03 Applied Materials, Inc. Stress management for tensile films
US8449942B2 (en) 2009-11-12 2013-05-28 Applied Materials, Inc. Methods of curing non-carbon flowable CVD films
US20110136241A1 (en) 2009-12-08 2011-06-09 Stephen Naylor Type ii diabetes molecular bioprofile and method and system of using the same
SG182336A1 (en) 2010-01-06 2012-08-30 Applied Materials Inc Flowable dielectric using oxide liner
JP5823505B2 (ja) 2010-05-21 2015-11-25 ザ・ガバナーズ・オブ・ザ・ユニバーシティー・オブ・アルバータ 尿中の代謝産物を測定することによる結腸直腸癌および結腸直腸ポリープの査定方法
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
SG11201502693SA (en) 2012-10-09 2015-05-28 Liposcience Inc Nmr quantification of branched chain amino acids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JEYARAJAH, E. J. et al, 'Lipoprotein Particle Analysis by Nuclear Magnetic Resonance Spectroscopy', Clinics in Laboratory Medicine, 1 December 2006, Vol. 26, No. 4, Pages 847-870. *

Also Published As

Publication number Publication date
HK1207156A1 (en) 2016-01-22
US10852293B2 (en) 2020-12-01
EP2859339B1 (en) 2020-10-28
US20170003269A1 (en) 2017-01-05
AU2013272014A1 (en) 2014-12-18
EP4439587A3 (en) 2024-12-18
US20210080452A1 (en) 2021-03-18
EP2859339A4 (en) 2016-08-03
CA2874550A1 (en) 2013-12-12
JP6177899B2 (ja) 2017-08-09
CN104508471A (zh) 2015-04-08
JP2015522806A (ja) 2015-08-06
WO2013184483A1 (en) 2013-12-12
FI3839544T3 (fi) 2024-12-27
SG11201407803TA (en) 2014-12-30
EP2859339A1 (en) 2015-04-15
CN104508471B (zh) 2017-09-19
CA3146947A1 (en) 2013-12-12
US20130328561A1 (en) 2013-12-12
CA2874550C (en) 2022-04-19
EP4439587A2 (en) 2024-10-02
US9470771B2 (en) 2016-10-18
EP3839544A1 (en) 2021-06-23
US11692995B2 (en) 2023-07-04
EP3839544B1 (en) 2024-10-02

Similar Documents

Publication Publication Date Title
US11692995B2 (en) NMR measurements of NMR biomarker GlycA
US20240096497A1 (en) Multi-Parameter Diabetes Risk Evaluations
US20220137076A1 (en) Cardiovascular Risk Evaluations Using a Risk Parameter That Includes an HDL and Inflammatory Biomarker Interaction Parameter
HK40055406A (en) Nmr measurements of glyca for determining coronary heart disease risk
HK40055406B (en) Nmr measurements of glyca for determining coronary heart disease risk
HK1207156B (en) Nmr measurements of glyca
HK40108481A (en) Multi-parameter diabetes risk evaluations

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)